WeVote
Log In

Bill

Bill

S 1817

Expedited Removal Expansion Act of 2025

119th Congress Introduced by Eric Schmitt

Bill S 1817 promotes clinical research on ibogaine as a potential drug addiction treatment, aiming to provide new options for those struggling with substance use disorders.

Introduced in Senate
0
WeVote Research Nonpartisan
Bill Summary · S 1817

Summary of Bill S 1817

Bill Information

  • Bill Number: S 1817
  • Title: Requires the office of addiction services and supports to encourage, aid, and facilitate clinical research into the use of ibogaine in drug treatment
  • Status: Referred to Alcoholism and Substance Use Disorders
  • Introduced: January 14, 2025
  • Classification: Bill

Purpose and Intent

Bill S 1817 aims to promote clinical research into the use of ibogaine, a naturally occurring psychoactive substance, as a potential treatment for drug addiction. The bill seeks to empower the office of addiction services and supports to actively encourage and facilitate studies that explore the efficacy and safety of ibogaine in treating substance use disorders.

Key Provisions

  • Encouragement of Research: The bill mandates the office of addiction services and supports to take proactive steps in promoting clinical research on ibogaine.
  • Support for Clinical Trials: It includes provisions for aiding researchers in the design and implementation of clinical trials focused on ibogaine's therapeutic potential.
  • Collaboration with Institutions: The bill encourages partnerships with academic and research institutions to advance the understanding of ibogaine in drug treatment contexts.

Impact

  • Target Population: The primary beneficiaries of this bill would be individuals struggling with substance use disorders who may benefit from alternative treatment options, particularly those who have not found success with traditional therapies.
  • Research Community: The bill would also impact researchers and healthcare professionals by providing a framework for investigating new treatment modalities in addiction medicine.
  • Policy Development: Should the research yield positive results, the findings could influence future policies and funding related to addiction treatment strategies.

Procedural Aspects

  • Current Status: As of January 14, 2025, the bill has been referred to the committee on Alcoholism and Substance Use Disorders for further consideration.
  • Related Legislation: This bill is related to prior-session Bill S 6180 and has a companion bill, A 1522, which may address similar issues or provide additional context for the legislative effort.

Conclusion

Bill S 1817 represents a significant step towards exploring innovative treatment options for drug addiction through the clinical study of ibogaine. By facilitating research in this area, the bill aims to expand the toolkit available to healthcare providers and improve outcomes for individuals facing substance use challenges.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.